Cocrystal to present Phase 1 data for norovirus inhibitor CDI-988 at Calicivirus Conference

Cocrystal Pharma, Inc.

CDI-988 is a first-in-class pan-viral protease inhibitor targeting norovirus and coronaviruses.
Oral presentation by co-CEO Sam Lee on Sept 11, 2025 at the 9th International Calicivirus Conference in Banff.
Phase 1 study completed evaluating safety, tolerability, pharmacokinetics, and food effect in healthy adults.
No approved vaccine or antiviral exists for norovirus; CDI-988 targets a conserved region of 3CL protease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.